Patients with chondrocalcinosis may present with a range of symptoms. The most common is sudden, severe joint pain, often accompanied by swelling and redness, resembling an acute gout attack. This is why it is sometimes called pseudogout. The knee is the most frequently affected joint, but other joints like the wrists, shoulders, and hips can also be involved. Some patients may experience chronic joint pain and stiffness, similar to osteoarthritis.

Diagnosing chondrocalcinosis involves a combination of clinical evaluation and imaging studies. X-rays are often used to detect the presence of calcium deposits in the cartilage, which appear as white lines or spots. Joint aspiration, where fluid is drawn from the affected joint, can be performed to identify CPPD crystals under a microscope. Blood tests may be conducted to rule out other conditions like gout or rheumatoid arthritis.

Treatment for chondrocalcinosis focuses on managing symptoms, as there is no cure for the condition. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain and inflammation. In more severe cases, corticosteroid injections into the affected joint may be recommended. Colchicine, a medication used for gout, can also be effective in preventing attacks. Physical therapy may help improve joint function and mobility.

The prognosis for chondrocalcinosis varies. Some individuals experience infrequent attacks with long periods of remission, while others may have chronic symptoms. Although the condition can be painful and affect quality of life, it is not life-threatening. With appropriate management, many patients can maintain a good level of function and comfort.

The exact cause of chondrocalcinosis is not fully understood. It is believed to be related to the aging process, as the condition is more common in older adults. Genetic factors may also play a role, as some families have a higher incidence of the disease. Other associated conditions include hyperparathyroidism, hemochromatosis, and hypomagnesemia, which can contribute to crystal formation.

Chondrocalcinosis is a relatively common condition, particularly among the elderly. It is estimated to affect up to 10% of people over the age of 60. The prevalence increases with age, and it is slightly more common in women than in men. The condition can occur worldwide, with no specific geographic or ethnic predilection.

The pathophysiology of chondrocalcinosis involves the deposition of calcium pyrophosphate crystals in the cartilage. These crystals can trigger an inflammatory response, leading to joint pain and swelling. The exact mechanism of crystal formation is not well understood, but it may involve an imbalance in the production and breakdown of pyrophosphate, a natural substance in the body.

There is no known way to prevent chondrocalcinosis entirely, but managing underlying conditions that contribute to crystal formation can help reduce the risk. This includes maintaining normal levels of calcium and magnesium, and treating conditions like hyperparathyroidism and hemochromatosis. Regular exercise and a healthy diet may also support joint health.

Chondrocalcinosis is a joint condition caused by the deposition of calcium pyrophosphate crystals, leading to pain and inflammation. It is most common in older adults and can mimic gout, hence the term pseudogout. Diagnosis involves imaging and joint fluid analysis, while treatment focuses on symptom management. Although the condition can be chronic, it is manageable with appropriate care.

If you have been diagnosed with chondrocalcinosis, it's important to understand that while there is no cure, the condition can be managed effectively. Treatment options are available to help control pain and improve joint function. Regular follow-ups with your healthcare provider, along with lifestyle modifications, can help you maintain a good quality of life. Remember to discuss any concerns or symptoms with your doctor to tailor a treatment plan that suits your needs.

1. Currie WJ. The gout patient in general practice. Rheumatol Rehabil. Nov 1978; 17(4):205-17.
2. Ciancio G, Bortoluzzi A, Govoni M. Epidemiology of gout and chondrocalcinosis. Reumatismo. Jan 19 2012; 63(4):207-20.
3. Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population.Rheumatology (Oxford). Nov 2012; 51(11):2070-4.
4. Watanabe H, Yamada S, Anayama S, Sato E, Maekawa S, Sugiyama H, et al. Pseudogout attack induced during etidronate disodium therapy. Mod Rheumatol. 2006; 16(2):117-9.
5. Taggarshe D, Ng CH, Molokwu C, Singh S. Acute pseudogout following contrast angiography. Clin Rheumatol. Feb 2006; 25(1):115-6.
6. Ogawa Y, Nagatsuma M, Kubota G, Inoue G. Acute lumbar spinal pseudogout attack after instrumented surgery. Spine (Phila Pa 1976). 2012; 37(24):E1529-33 (
7. Busso N, Ea HK. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo. 2011; 63(4):230-7 
8. Yoo Y, Seo YJ, Huh M. Gout and coexisting pseudogout in the knee joint. Knee Surg Sports Traumatol Arthrosc. 2011; 19(4):553-5
9. Srinivasan V, Kesler H, Johnson M. Tophaceous pseudogout of the thoracic spine. Acta Neurochir (Wien). 2012; 154(4):747-50; discussion 750
10. Lin SH, Hsieh ET, Wu TY, Chang CW. Cervical myelopathy induced by pseudogout in ligamentum flavum and retro-odontoid mass: a case report. Spinal Cord. Nov 2006; 44(11):692-4.a